MYOV - Myovant Sciences Ltd.

NYSE - NYSE Delayed Price. Currency in USD
11.37
+0.20 (+1.79%)
At close: 4:02PM EST

11.37 0.00 (0.00%)
After hours: 4:45PM EST

Stock chart is not supported by your current browser
Previous Close11.17
Open11.13
Bid11.24 x 800
Ask11.48 x 800
Day's Range10.94 - 11.64
52 Week Range4.14 - 26.02
Volume455,931
Avg. Volume1,389,601
Market Cap1.021B
Beta (5Y Monthly)2.06
PE Ratio (TTM)N/A
EPS (TTM)-3.69
Earnings DateFeb 09, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.83
  • Is the Options Market Predicting a Spike in Myovant (MYOV) Stock?
    Zacks

    Is the Options Market Predicting a Spike in Myovant (MYOV) Stock?

    Investors need to pay close attention to Myovant (MYOV) stock based on the movements in the options market lately.

  • GlobeNewswire

    Myovant Sciences Provides Recent Corporate Updates and Reports Financial Results for Third Fiscal Quarter Ended December 31, 2019

    - 96.7% response rate in Phase 3 HERO study support submission of New Drug Application (NDA) for relugolix monotherapy tablet for advanced prostate cancer in the second quarter.

  • GlobeNewswire

    Myovant Sciences Announces 88% One-Year Response Rate in Positive Phase 3 LIBERTY Extension Study of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids

    Myovant Sciences (MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, today announced that the Phase 3 LIBERTY open-label extension study of once-daily, oral relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg) demonstrated an 87.7% response rate at one year while maintaining bone mineral density. Myovant expects to include the extension data in its New Drug Application (NDA) submission for heavy menstrual bleeding associated with uterine fibroids anticipated in April 2020.

  • Former Genentech exec looks to replicate that 'magical time' with new biotech model
    American City Business Journals

    Former Genentech exec looks to replicate that 'magical time' with new biotech model

    Myrtle Potter wants Sumitovant to "keep thinking about complex problems and stay scrappy and stay focused on the programs that make a difference for patients."

  • MoneyShow

    Top Picks 2020- Myovant Sciences Ltd. MYOV

    Myovant Sciences Ltd. (MYOV) offers a new drug "pipeline in a pill", asserts biotech expert Jay Silverman, contributing editor to The Medical Technology Stock Letter.

  • GlobeNewswire

    Myovant Sciences to Present at the 38th Annual J.P. Morgan Healthcare Conference

    BASEL, Switzerland, Jan. 06, 2020 -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer,.

  • GlobeNewswire

    Myovant Sciences Announces Closing of $400 Million Loan Facility, Repayment of Debt, Board of Director Transitions, and Executive Promotions

    Low-interest (3-month LIBOR plus 3%) loan facility from Sumitomo Dainippon Pharma increased to allow repayment of pre-existing debtHiroshi Nomura, President, CEO, and.

  • Hedge Funds Had Impeccable Timing Buying Myovant Sciences Ltd. (MYOV)
    Insider Monkey

    Hedge Funds Had Impeccable Timing Buying Myovant Sciences Ltd. (MYOV)

    Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]

  • Should You Be Concerned About Myovant Sciences Ltd.'s (NYSE:MYOV) Historical Volatility?
    Simply Wall St.

    Should You Be Concerned About Myovant Sciences Ltd.'s (NYSE:MYOV) Historical Volatility?

    Anyone researching Myovant Sciences Ltd. (NYSE:MYOV) might want to consider the historical volatility of the share...

  • Biotech Tops in November: Best ETFs & Stocks
    Zacks

    Biotech Tops in November: Best ETFs & Stocks

    The biotech space of the broad healthcare sector outperformed others in November, courtesy of a series of positive news including study results, regulatory backdrop and deal activities.

  • Myovant (MYOV) Catches Eye: Stock Jumps 6.7%
    Zacks

    Myovant (MYOV) Catches Eye: Stock Jumps 6.7%

    Myovant (MYOV) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

  • GlobeNewswire

    Myovant Sciences to Present at the Evercore ISI 2nd Annual HealthCONx Conference on December 3, 2019

    Myovant Sciences (MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, today announced that Lynn Seely, M.D., Myovant’s President and CEO, will present at the Evercore ISI 2nd Annual HealthCONx Conference on Tuesday, December 3, 2019 at 10:35 a.m. Eastern Time in Boston, MA. A live webcast of the presentation will be accessible on the Events page under the Investors & Media section of the Myovant website at www.myovant.com. Myovant Sciences aspires to be the leading healthcare company focused on innovative treatments for women’s health and prostate cancer.

  • Benzinga

    Fighting FOMO And Finding Profit In Consistency

    One of the biggest things I’ve tried to stress in my training for this upcoming small account challenge, both to myself and to my students, is that my daily profits are not going to be as mind-bogglingly ...

  • Biotech Stock Roundup: MYOV & KRTX Surge, Pipeline Updates From VRTX, CELG & More
    Zacks

    Biotech Stock Roundup: MYOV & KRTX Surge, Pipeline Updates From VRTX, CELG & More

    Key highlights of the past week include regulatory and pipeline updates along with collaboration deals.

  • Myovant Up on Successful Completion of Prostate Cancer Study
    Zacks

    Myovant Up on Successful Completion of Prostate Cancer Study

    Myovant's (MYOV) phase III study evaluating lead pipeline candidate, relugolix, in patients with advanced prostate cancer meets primary endpoint.

  • With prostate cancer trial done, Peninsula drug maker will ask for FDA approval early next year
    American City Business Journals

    With prostate cancer trial done, Peninsula drug maker will ask for FDA approval early next year

    Myovant Sciences also will seek FDA approval next year of a different version of the same drug to treat heavy menstrual bleeding in women with uterine fibroids.

  • Benzinga

    Myovant's Stock Soars After Relugolix Aces Late-Stage Study For Prostate Cancer

    Shares of thinly-traded, small-cap biotech Myovant Sciences Ltd (NYSE: MYOV ) are skyrocketing Tuesday, the catalyst being a positive late-stage clinical readout . What Myovant Said About Relugolix Myovant ...

  • Benzinga

    The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 18) 10X Genomics Inc (NASDAQ: TXG )(IPOed Sept. 12) 89bio ...

  • GlobeNewswire

    Myovant Sciences Announces 97% Response Rate in Positive Phase 3 HERO Study of Once-Daily, Oral Relugolix in Men with Advanced Prostate Cancer

    Myovant Sciences (MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, today announced that the Phase 3 HERO study of once-daily, oral relugolix (120 mg) met its primary efficacy endpoint and all six key secondary endpoints in men with advanced prostate cancer. “An oral gonadotropin-releasing hormone, or GnRH, antagonist for advanced prostate cancer has been an aspiration for many years,” said Neal Shore, M.D., Medical Director of the Carolina Urologic Research Center and HERO Program Steering Committee Member.

  • GlobeNewswire

    Myovant Sciences to Host Webcast and Conference Call at 8:30 a.m. Eastern Time Tuesday, November 19 to Discuss Results from Phase 3 Study Evaluating Once-Daily, Oral Relugolix in Men with Advanced Prostate Cancer

    BASEL, Switzerland, Nov. 18, 2019 -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer,.

  • GlobeNewswire

    Myovant Sciences Provides Recent Corporate Updates and Reports Financial Results for Second Fiscal Quarter Ended September 30, 2019

    Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women’s health and prostate cancer, today announced recent corporate updates and reported financial results for the second fiscal quarter ended September 30, 2019. “Myovant continues to make great progress towards our milestones and is poised for a strong commercial launch of relugolix if approved, with two positive Phase 3 studies evaluating relugolix combination therapy in women with uterine fibroids and approximately $500 million in total cash and committed financing, including the Sumitomo Dainippon Pharma term loan facility,” said Lynn Seely, M.D., President and CEO of Myovant Sciences.

  • Myovant Sciences Ltd. (MYOV): Are Hedge Funds Right About This Stock?
    Insider Monkey

    Myovant Sciences Ltd. (MYOV): Are Hedge Funds Right About This Stock?

    Investing in small cap stocks has historically been a way to outperform the market, as small cap companies typically grow faster on average than the blue chips. That outperformance comes with a price, however, as there are occasional periods of higher volatility. The last 12 months is one of those periods, as the Russell 2000 […]

  • Goldman Sachs: 3 Standout Healthcare Stocks That Could Double
    TipRanks

    Goldman Sachs: 3 Standout Healthcare Stocks That Could Double

    The S&P 500 closed at an all time high on Monday evening -- then closed at an even higher high on Wednesday -- 3,046.77. Goldman Sachs believes this rally could keep going well into 2020.A recent report from Goldman Sachs predicts that 2020 will see corporations spend nearly a half-trillion dollars on stock buybacks, mergers, and acquisitions next year. Add in buying by U.S. individual investors and foreign investors, and that buying could be pushed well beyond the $500 billion-mark, says Goldman Sachs analyst David Kostin, as investors seek to profit from "positive equity market returns," buoyed by "rising interest rates, and stabilizing US and World GDP growth."But where do you look to find those profits specifically?Using the Stock Screener at TipRanks to seek out highly rated stocks in the ever-growing healthcare sector, for which Goldman Sachs analysts expect to see double, near double, or more than double returns in the next 12 months, we've come up with three candidates for you today.Arvinas Holding (ARVN)Based in New Haven, Connecticut, cancer-fighter Arvinas is researching therapies to degrade cancer-causing proteins in diseases such as prostate cancer and breast cancer.Goldman Sachs analyst Terence Flynn upgraded Arvinas to "buy" with a $38 price target after reviewing the result of Phase 1 clinical trials of the company's ARV-110 (for prostate cancer) and ARV-471 (for breast cancer) drugs. (To watch Flynn's track record, click here)As the label "Phase 1" suggests, Flynn admits that "trials are still in the early stages," but initial safety data looks good, opening a path to proceed to evaluating "first clinical efficacy data." Flynn increases his probability of success for both ARV-110 and ARV-471 to 25% (vs. 20% prior) given the initial safety/PK data presented, which in his view "provide some incremental de-risking of the drugs."If all goes well, Flynn foresees "blockbuster potential" for both drugs, with potential peak sales of $2.9 billion and $4.7 billion, respectively -- a big improvement over the $15 million in revenue Arvinas has booked over the last 12 months.Street sentiment on this one is good as well, with three analysts initiating coverage of Arvinas over the last three months -- in addition to Goldman's upgrade. And like Goldman, all three of these other analysts rate the stock a "buy," which qualifies the stock for "strong buy" sentiment in our book. A consensus target price of $38 (in line with Goldman's own target price) implies 81% upside for the shares over the next 12 months. (See Arvinas stock analysis on TipRanks)Livongo Health (LVGO)Next up: taking a different path to healthcare, Livongo Health is a Mountain View, California, software company seeking to harness data to improve patient outcomes in the fields of hypertension treatment, diabetes care, and weight management.This one attracted the attention of Goldman Sachs analyst Robert Jones, after Livongo was awarded a contract "to provide the Livongo for Diabetes solution to eligible members covered by the Federal Employees Health Benefits program under one health plan covering 5.3mn lives." Beginning on January 1, 2020, and for at least nine to 12 months thereafter, Livongo will work to reduce diabetes in the federal workforce -- and receive between $20 million and $25 million for its services in 2020, and perhaps $30 million to $35 million in 2021 if all goes well.This single contract, therefore, holds the potential to grow Livongo's $113 million in trailing revenues by 22% next year -- and push Livongo stock up as high as $43 a share, in Jones' estimation, over the next 12 months.The rest of Wall Street is even more optimistic. More than half a dozen analysts have chimed in over the past couple of months, most with buy ratings, and with an average price target of $43.63. If they're right, that means Livongo stock could more than double over the next 12 months. (See Livongo stock analysis on TipRanks)Myovant Sciences (MYOV) Returning to the pharmaceutical field now, but shifting our gaze to the UK, London-based Myovant Sciences is a clinical-stage biopharmaceutical company working to develop drugs for use in women's health, with backing from Japan's Sumitomo Dainippon Pharma, which took a 46% stake in the company last quarter and is helping to move Myovant towards commercial production.Goldman Sachs analyst Paul Choi isn't looking for earnings to be much of a catalyst for the stock (because there are none). But sales revenue is anticipated to begin rolling in next year, and could quadruple to more than $153 million by 2021. Furthermore, Choi recommends the stock in anticipation of the companies signing a "definitive agreement" of their partnership, assigning Myovant stock a "buy" rating and an $18 price target. (To watch Choi's track record, click here)Wall Street as a whole is similarly bullish, with three "buy" ratings filed in the last two months (including Goldman's), making the stock a "Strong Buy" according to TipRanks. With Street analysts positing an average $22 average price target, Myovant shows the most profit potential of all on today's list -- 325% to be exact. (See Myovant stock analysis on TipRanks)